$TOVX
Theriva Biologics, Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420414068250 Filed on November 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.860M $1.220M $1.560M
YoY Change 19.23% -35.45% 81.4%
% of Gross Profit
Research & Development $5.240M $3.693M $2.710M
YoY Change 93.36% 150.37% -75.43%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $10.00K
YoY Change 0.0% -100.0% 0.0%
% of Gross Profit
Operating Expenses $7.100M $4.911M $4.270M
YoY Change 66.28% 45.94% -64.09%
Operating Profit -$4.911M
YoY Change 45.94%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $620.0K $1.000K $50.00K
YoY Change 1140.0% -133.33% -225.0%
Pretax Income -$7.101M -$4.911M -$4.273M
YoY Change 66.18% 45.94% -64.06%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.480M -$4.910M -$4.225M
YoY Change 53.37% 45.78% -65.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$3.115M -$0.08 -$3.036M
COMMON SHARES
Basic Shares Outstanding 72.51M shares 58.45M shares 44.65M shares
Diluted Shares Outstanding 58.45M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.53M $3.290M $14.63M
YoY Change 19.82% -36.12% 47.04%
Cash & Equivalents $17.53M $3.286M $14.63M
Short-Term Investments
Other Short-Term Assets $1.548M $1.382M $1.591M
YoY Change -2.7% -16.09% -36.59%
Inventory
Prepaid Expenses $253.0K $193.0K $53.00K
Receivables
Other Receivables
Total Short-Term Assets $19.07M $4.668M $16.22M
YoY Change 17.62% -31.27% 30.11%
LONG-TERM ASSETS
Property, Plant & Equipment $65.00K $67.00K $37.00K
YoY Change 75.68% -57.32% -83.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $0.00
YoY Change -100.0%
Total Long-Term Assets $71.00K $73.00K $41.00K
YoY Change 73.17% -54.66% -95.73%
TOTAL ASSETS
Total Short-Term Assets $19.07M $4.668M $16.22M
Total Long-Term Assets $71.00K $73.00K $41.00K
Total Assets $19.14M $4.741M $16.26M
YoY Change 17.76% -31.81% 21.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $996.0K $873.0K $142.0K
YoY Change 601.41% 49.49% -64.05%
Accrued Expenses $1.298M $111.0K $882.0K
YoY Change 47.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.588M $984.0K $1.027M
YoY Change 833.59% 69.66% 160.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.588M $984.0K $1.027M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $9.588M $984.0K $1.027M
YoY Change 833.59% 68.49% 160.0%
SHAREHOLDERS EQUITY
Retained Earnings -$101.0M -$94.56M -$81.26M
YoY Change 24.35% 22.75% 17.87%
Common Stock $110.6M $98.32M $96.49M
YoY Change 14.62% 17.88% 17.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.556M $3.757M $15.23M
YoY Change
Total Liabilities & Shareholders Equity $19.14M $4.741M $16.26M
YoY Change 17.76% -31.81% 21.11%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$6.480M -$4.910M -$4.225M
YoY Change 53.37% 45.78% -65.0%
Depreciation, Depletion And Amortization $10.00K $0.00 $10.00K
YoY Change 0.0% -100.0% 0.0%
Cash From Operating Activities -$4.780M -$4.530M -$2.700M
YoY Change 77.04% 163.37% -43.51%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$20.00K -$10.00K
YoY Change 0.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$20.00K -$10.00K
YoY Change 0.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.03M 0.000 12.20M
YoY Change 55.98% 20.2%
NET CHANGE
Cash From Operating Activities -4.780M -4.530M -2.700M
Cash From Investing Activities -10.00K -20.00K -10.00K
Cash From Financing Activities 19.03M 0.000 12.20M
Net Change In Cash 14.24M -4.550M 9.490M
YoY Change 50.05% 161.49% 76.72%
FREE CASH FLOW
Cash From Operating Activities -$4.780M -$4.530M -$2.700M
Capital Expenditures -$10.00K -$20.00K -$10.00K
Free Cash Flow -$4.770M -$4.510M -$2.690M
YoY Change 77.32% 165.29% -43.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1382000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3286000 USD
CY2014Q3 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
6000 USD
CY2014Q3 us-gaap Assets
Assets
4741000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
4668000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
873000 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
58000 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98261000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94562000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
3757000 USD
CY2014Q3 us-gaap Minority Interest
MinorityInterest
0 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3757000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4741000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
111000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
96430000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
984000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
15230000 USD
CY2013Q4 us-gaap Minority Interest
MinorityInterest
0 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15230000 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
58000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81258000 USD
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58295808 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58214326 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2014Q2 dei Entity Public Float
EntityPublicFloat
75000000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14625000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1591000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
16216000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000 USD
CY2013Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4000 USD
CY2013Q4 us-gaap Assets
Assets
16257000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
142000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
885000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1027000 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16257000 USD
CY2014Q3 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1073000 USD
CY2013Q4 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1361000 USD
CY2014Q3 us-gaap Prepaid Insurance
PrepaidInsurance
51000 USD
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
177000 USD
CY2014Q3 syn Prepaid Credit Cards
PrepaidCreditCards
65000 USD
CY2013Q4 syn Prepaid Credit Cards
PrepaidCreditCards
0 USD
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
193000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
53000 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1382000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1591000 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
99000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
56000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19000 USD
syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price One
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne
1.74
CY2013Q3 syn Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price One
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.48 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2013Q3 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2014Q3 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2013 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
232619 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
454896 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
944986 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2013 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.47
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.88
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.16
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58535010 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58453528 shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4270000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4154000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1218000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3796000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9247000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1475000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3693000 USD
us-gaap Operating Expenses
OperatingExpenses
8066000 USD
us-gaap Operating Expenses
OperatingExpenses
13401000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
3365000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
4911000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8066000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13401000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3365000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4911000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
32000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
95000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
97000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
us-gaap Profit Loss
ProfitLoss
-8093000 USD
us-gaap Profit Loss
ProfitLoss
-13304000 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-3368000 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
-4910000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2013Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2014Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-8093000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13304000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3368000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4910000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44636935 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58356025 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44654414 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58453528 shares
us-gaap Share Based Compensation
ShareBasedCompensation
1202000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1827000 USD
us-gaap Depreciation
Depreciation
33000 USD
us-gaap Depreciation
Depreciation
13000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-58000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-800000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-209000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-33000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
2000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
189000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
731000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-774000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5015000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11300000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-43000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
231000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
4000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
231000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4809000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-11339000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9954000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5145000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
SYN
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72513144 shares
CY2014Q3 us-gaap Liabilities
Liabilities
984000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
1027000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
763000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD

Files In Submission

Name View Source Status
0001144204-14-068250-index-headers.html Edgar Link pending
0001144204-14-068250-index.html Edgar Link pending
0001144204-14-068250.txt Edgar Link pending
0001144204-14-068250-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20140930.xml Edgar Link completed
syn-20140930.xsd Edgar Link pending
syn-20140930_cal.xml Edgar Link unprocessable
syn-20140930_def.xml Edgar Link unprocessable
syn-20140930_lab.xml Edgar Link unprocessable
syn-20140930_pre.xml Edgar Link unprocessable
tpg12.jpg Edgar Link pending
v393218_10q.htm Edgar Link pending
v393218_ex31-1.htm Edgar Link pending
v393218_ex31-2.htm Edgar Link pending
v393218_ex32-1.htm Edgar Link pending
v393218_ex32-2.htm Edgar Link pending